H
Hugh Watson
Researcher at Aarhus University
Publications - 49
Citations - 1364
Hugh Watson is an academic researcher from Aarhus University. The author has contributed to research in topics: Cirrhosis & Ascites. The author has an hindex of 13, co-authored 37 publications receiving 1141 citations. Previous affiliations of Hugh Watson include Aarhus University Hospital.
Papers
More filters
Journal ArticleDOI
Hyponatremia in cirrhosis: Results of a patient population survey.
TL;DR: Low serum sodium levels in cirrhosis are associated with severe ascites and high frequency of hepatic encephalopathy, spontaneous bacterial peritonitis, and hepatorenal syndrome.
Journal ArticleDOI
Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial
TL;DR: The V2 receptor antagonist satavaptan improves the control of ascites and increases serum sodium in patients with cirrhosis, ascites, and hyponatremia under diuretic treatment.
Journal ArticleDOI
Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites
TL;DR: PPIs were used by 52% of this international cirrhosis cohort during a 1‐year period and was a risk factor for developing HE and SBP, consistent with the hypothesis that PPIs may increase translocation of gut bacteria.
Journal ArticleDOI
Factors related to quality of life in patients with cirrhosis and ascites: Relevance of serum sodium concentration and leg edema
Elsa Solà,Hugh Watson,Isabel Graupera,Fanny Turon,Rogelio Barreto,Ezequiel Rodríguez,Marco Pavesi,Vicente Arroyo,Mónica Guevara,Pere Ginès +9 more
TL;DR: Serum sodium concentration and presence of leg edema are major factors of the impaired HRQL in patients with cirrhosis and ascites.
Journal ArticleDOI
Nonselective β‐blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients
TL;DR: In this paper, the safety of nonselective β-blockers (NSBBs) in advanced cirrhosis has been questioned, and a large and detailed data set on worldwide non-protocol use of NSBBs in patients with ascites is presented.